Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

2.

Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.

Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K.

Rheumatol Ther. 2020 Mar;7(1):89-99. doi: 10.1007/s40744-019-00181-8. Epub 2019 Nov 16.

3.

Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.

Khanna D, Jahreis A, Lin CJF.

Ann Rheum Dis. 2019 Nov;78(11):e124. doi: 10.1136/annrheumdis-2018-214477. Epub 2018 Oct 23. No abstract available.

PMID:
30352886
4.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

5.

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, Jahreis A, Zhang Y, Siegel J, Lafyatis R.

Arthritis Rheumatol. 2018 Jun;70(6):912-919. doi: 10.1002/art.40455.

6.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.

7.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

8.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

9.

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE.

Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5. Erratum in: Lancet. 2018 Apr 7;391(10128):1356.

PMID:
27156934
10.

Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis.

Lehane PB, Lacey S, Hessey EW, Jahreis A.

Ann Rheum Dis. 2014 Oct;73(10):1906-8. doi: 10.1136/annrheumdis-2014-205474. Epub 2014 Jul 29. No abstract available.

11.

Using registries to identify adverse events in rheumatic diseases.

Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.

Pediatrics. 2013 Nov;132(5):e1384-94. doi: 10.1542/peds.2013-0755. Epub 2013 Oct 21. Review.

12.

Integrated safety in tocilizumab clinical trials.

Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF.

Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455. Epub 2011 Sep 1.

13.

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.

Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.

15.

A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis.

Cardiel MH, Tak PP, Bensen W, Burch FX, Forejtova S, Badurski JE, Kakkar T, Bevirt T, Ni L, McCroskery E, Jahreis A, Zack DJ.

Arthritis Res Ther. 2010;12(5):R192. doi: 10.1186/ar3163. Epub 2010 Oct 15.

16.

Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.

Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A.

J Drugs Dermatol. 2010 Aug;9(8):928-37.

PMID:
20684143
17.

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.

Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A, Globe D, Patel V, Orlow SJ.

J Am Acad Dermatol. 2011 Jan;64(1):64-70. doi: 10.1016/j.jaad.2010.02.060. Epub 2010 Jul 8.

PMID:
20619489
18.

Etanercept treatment for children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group.

N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.

19.

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.

Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A.

Br J Dermatol. 2007 Dec;157(6):1275-7. Epub 2007 Oct 4. No abstract available.

PMID:
17916204
20.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.

Arch Dermatol. 2007 Jun;143(6):719-26.

PMID:
17576937

Supplemental Content

Loading ...
Support Center